08:42 EDT uniQure (QURE) soars 167% to $36.50 in pre-market after AMT-130 study met endpoint
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QURE:
- uniQure announces Phase I/II study of AMT-130 met primary endpoint
- uniQure selloff on data absence an opportunity, says Mizuho
- Buy Rating for uniQure Driven by Promising Gene Therapy Data and Future Growth Potential
- uniQure announces initial AMT-191 Phase I/IIa data
- Buy Rating for uniQure: Promising Developments in Huntington’s Disease Treatment AMT-130